Sample of Efficacy Study
Hepatitis B

Efficacy Study - Hepatitis B In Vivo

Studies in the PXB-Mouse® offer several advantages over other small animal models of Hepatitis B (HBV)

  • Studies of the human virus in human hepatocytes, infection with different genotypes and variants
  • Evaluation of agents interfering with viral entry, uncoating, nuclear transport, formation of cccDNA, transcription, replication of viral nucleic acid, translation of RNA and egress of the virus
  • Long-term stable viral titers
  • Possibility of super-infection or simultaneous infection with delta-virus (hepatitis D)
  • Exploiting the capability of HBV to interfere with pathways of the innate antiviral response in human hepatocytes

Standard measurements:

human serum albumin (hAlb)





Hepatitis B

In spite of the existence of an effective vaccine, approximately 360 million people worldwide are infected with hepatitis B virus (HBV). Although current antiviral therapy with nucleos(t)ide analogues can suppress viral replication, copies of the viral genome still persists within the infected hepatocytes in the form of cccDNA. 

Considering the narrow host range of hepatitis B, recently there has been significant interest in the application of the uPA/scid chimeric mouse model for HBV infection studies and preclinical drug evaluation.

PXB-Mouse® platform technology is a cost effective animal model that contributes important advantages to research on Hepatitis B and other liver related issues in drug development.